What's in Yuvell's pipeline?

Yuvell has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Yuvell's portfolio?

No competitive overlap detected.

Subscribe to /feed/company/yuvell.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Yuvell pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Drug	Generic	Phase	Class	Target	Area	First approval
Letybo®	Letybo®	marketed	FLT3 inhibitor / multi-targeted tyrosine kinase inhibitor	FLT3, JAK2	Oncology

No regulatory actions in the last 90 days for this portfolio.

No PDUFA dates in the next 180 days for this portfolio.

No upcoming patent expiries for this portfolio.

No competitive overlap data.

Every new pipeline event for Yuvell:

Drug Landscape (2026). Yuvell — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/yuvell. Accessed 2026-05-13.